Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

Huntsman Cancer Institute at the University of Utah is a nationally recognized research center and treatment hospital in Salt Lake City. We are the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West and serve patients with all types of cancer from Utah, Idaho, Montana, Nevada, and Wyoming. In 2021, we opened the region’s first proton therapy center. We manage the Utah Population Database, the largest genetic database in the world. More genes for inherited cancers have been discovered at our institution than any place in the world, including genes for melanoma and breast, ovarian, colon, head, and neck cancers.

Connect with us:

Latest from Huntsman Cancer Institute at the University of Utah


Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

November 28, 2023

Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.

Comparing Treatment Combinations in Renal Cell Carcinoma

November 28, 2023

A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.

New Clinical Trials Test Innovative Ways To Preserve Muscle Mass During Metastatic Prostate Cancer

October 25, 2023

The National Cancer Institute awarded investigators at Huntsman Cancer Institute a grant totaling more than $3 million to conduct a clinical trial to see if combining creatine monohydrate supplementation and resistance exercise training helps preserve muscle in people who have metastatic prostate cancer.

Dr Agarwal on Future Questions to Address Following the TALAPRO-2 Trial in mCRPC

July 26, 2023

Neeraj Agarwal, MD, discusses future questions to be addressed following the phase 3 TALAPRO-2 trial evaluating the combination of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 17, 2023

Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data from the TALAPRO-2 trial, and how this combination further supports the use of PARP inhibitors in the mCRPC treatment paradigm.

Dr Agarwal on Advances With PARP Inhibitors in Prostate Cancer

July 10, 2023

Neeraj Agarwal, MD, discusses the role of PARP inhibitors in metastatic castration-resistant prostate cancer and the potential evolutions of the metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer treatment paradigms.

Dr Agarwal on the FDA Approval of Talazoparib Plus Enzalutamide in HRR-Mutated mCRPC

July 06, 2023

Neeraj Agarwal, MD, discusses the significance of the FDA approval of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.

Addressing Health in Areas Characterized by Persistent Poverty

July 06, 2023

The Center for Health Outcomes and Population Equity at Huntsman Cancer Institute and the University of Utah, in partnership with the Montana State University Center for American Indian and Rural Health Equity, received a grant for Cancer Control in Persistent Poverty Areas from the National Cancer Institute.